Maha Hussain, M.D., Joaquin Mateo, M.D., Karim Fizazi, M.D., Fred Saad, M.D., Neal Shore, M.D., Shahneen Sandhu, M.D., Kim N. Chi, M.D., Oliver Sartor, M.D., Neeraj Agarwal, M.D., David Olmos, M.D., Antoine Thiery-Vuillemin, M.D., Przemyslaw Twardowski, M.D., et al., for the PROfound Trial Investigators*
Prostate cancer treatment interview with Dr. Neal Shore featured on WCSC Live 5 News
Click on the video below to watch the interview:
Karim Fizazi, M.D., Neal Shore, M.D., Teuvo L. Tammela, M.D., Ph.D., Albertas Ulys, M.D., Egils Vjaters, M.D., Sergey Polyakov, M.D., Mindaugas Jievaltas, M.D., Murilo Luz, M.D., Boris Alekseev, M.D., Iris Kuss, M.D., Marie-Aude Le Berre, M.Sc., Oana Petrenciuc, M.D., et al., for the ARAMIS Investigators*
‘Coming into their own’: FDA approval of liquid biopsy tests puts early, less invasive cancer detection in broader reach
First patient in treatment in RhoVac’s clinical phase IIb study in the USA
Dr. Neal D. Shore has been invited to join the prestigious Duke Global Health Institute Board of Advisors
The inaugural board of advisors for Duke Global Health Institute, founded in 2009, was composed of 14 visionary members who embraced Duke’s vision to build a world-class program that would lead its peers in the charge to address global health disparities. The work of that group played a vital role in developing DGHI into the establishment it is today, with over 400 students and 100 faculty from 8 Duke schools, conducting research in over 40 countries.
The DGHI board of advisors is entering its own phase of growth, from 15 to 25 members over the next five years. DGHI values board service and seeks to: 1) cultivate members’ interest in global health by providing opportunities for learning, meaningful discourse and interaction with leaders in the field; 2) honor its members’ contribution of time and effort by enlisting guidance and expertise on matters for which they can be most impactful; 3) foster in its members a sense of inspiration and purpose by facilitating interaction with students, faculty and staff; and 4) create an experience that deepens members’ affinity and connection to Duke University.
In creating a positive and engaging board experience, DGHI aims to empower its advisory board members to serve in a variety of ways: as thought partners, champions, investors and ambassadors who facilitate relationships and opportunities that support its mission. The DGHI advisory board convenes twice annually, once in the spring and another in the fall. Spring meetings rotate between New York, NY and Washington, DC; and fall meetings meet in Durham, NC. Terms of service last three years, and are renewable once by mutual agreement.
Dr. Shore’s educational and professional background, philanthropic investments, and alumnus status made him a fortuitous addition.
Presented by: Neal D. Shore, Paul F. Schellhammer, Ronald F. Tutrone, Neil F. Mariados, Stacey S. Harrelson
Johann de Bono, M.B., Ch.B., Ph.D., Joaquin Mateo, M.D., Ph.D., Karim Fizazi, M.D., Ph.D., Fred Saad, M.D., Neal Shore, M.D., Shahneen Sandhu, M.D., Kim N. Chi, M.D., Oliver Sartor, M.D., Neeraj Agarwal, M.D., David Olmos, M.D., Ph.D., Antoine Thiery-Vuillemin, M.D., Ph.D., Przemyslaw Twardowski, M.D., et al.
Neal D. Shore, M.D., Fred Saad, M.D., Michael S. Cookson, M.D., M.M.H.C., Daniel J. George, M.D., Daniel R. Saltzstein, M.D., Ronald Tutrone, M.D., Hideyuki Akaza, M.D., Alberto Bossi, M.D., David F. van Veenhuyzen, M.B., Ch.B., M.Pharm.Med., Bryan Selby, M.S., Xiaolin Fan, Ph.D., Vicky Kang, M.D., et al., for the HERO Study Investigators*
- Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial
- Understanding the Underutilization of Germline Genetic Testing in Prostate Cancer
- Dr. Shore Presents Practice-Changing Data In Prostate Cancer / EMBARK points to potential new standard of care for high-risk BCR.
- AUA Chicago April 28 – May 1, 2023- Here We Come